Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 3, 2016

Baxter Recalls Micron Filters

The company is voluntarily recalling all unexpired lots of 50-mm, 0.2-micron filters.

Baxter announced on Sept. 27, 2016 that it was voluntarily recalling all unexpired lots of 50-mm, 0.2-micron filters because of the potential for a missing filter support membrane and the potential presence of particulate matter. The component was manufactured by an external supplier, and the problems were identified by compounding pharmacies before the product reached patients.

The recalled filters, which filter bacteria and particulates, are used for aqueous solutions during compounding. According to Baxter, “In the absence of the filter support membrane, bacteria and/or particulate matter present in an unsterile solution could pass through to the compounded prepared solution. If not further filtered before patient administration, this could lead to adverse health consequences.”

The recalled lots were distributed between August 22, 2013 and June 20, 2016. The recalled product code is H93835, with an expiration date of June 27, 2016–June 27, 2019.

Source: FDA


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.